Mir-373 in tace selected hcc patients process: submission:08/20/2022 acceptance:01/05/2023 mirna-373 as predictor of response to therapy in hepatocellular carcinoma patients awaiting liver

HIGHLIGHTS

• who: Hepatitis-C virus- ALBI grade- et al. from the Program version, .1. according to (Hanley and McNeil, ) of , patients was found to be required to designate an area under the receiver operating characteristic curve (AUROC) ofas statistically significantly different from a null hypothesis AUROC of, ., (meaning no discriminating power), with a power of, % and at a significance level of, .05. Patients were recruited from the Intervention Radiology Department clinic, Alexandria University between April , and May, . The study was conducted on seventy-three subjects divided into fifty-three HCV infected HCC patients, referred for TACE as a . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.